{"nctId":"NCT01008423","briefTitle":"Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis","startDateStruct":{"date":"2009-11-20","type":"ACTUAL"},"conditions":["Proctitis","Proctosigmoiditis"],"count":281,"armGroups":[{"label":"Budesonide","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Budesonide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Voluntarily sign written informed consent.\n* Male or non-pregnant and non-lactating females.\n* Confirmed diagnosis (by endoscopy procedure) of active, mild to moderate UP or UPS, with disease extending at least 5 centimeters (cm) but no further than 40 cm from the anal verge.\n* Must possess a baseline MMDAI score between 5 and 10.\n\nExclusion Criteria:\n\n* History or current diagnosis of Crohn's disease and indeterminate colitis.\n* Prior gastrointestinal surgery except appendectomy and hernia.\n* Concomitant active gastrointestinal disease or distortion of intestinal anatomy.\n* History of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic or known gallbladder disease.\n* Uncontrolled, previously diagnosed type 1 or 2 diabetes mellitus.\n* Uncontrolled abnormal thyroid function.\n* Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.\n* Hemoglobin levels less than (\\<) 7.5 grams /deciliter (g/dL).\n* History of sclerosing cholangitis, cirrhosis, or hepatic impairment.\n* Renal disease manifested by greater than (\\>) 2.0 milligrams/deciliter (mg/dL) serum creatinine.\n* History of avascular hip necrosis, active tuberculosis, ocular herpes simplex or ocular varicella zoster, malignant disease, and HIV or hepatitis B or C.\n* Adrenal insufficiency.\n* Active systemic or cutaneous infection or toxic megacolon, fistula, perforation or abscess.\n* History of uncontrolled psychiatric disorders or seizure disorders.\n* History of asthma requiring ongoing use of inhaled steroids.\n* Recent history of drug or alcohol abuse.\n* Positive stool test for bacterial pathogens, Clostridium difficile toxin, or ovum and parasites.\n* Vaccination within 28 days prior to randomization.\n* Allergies to budesonide or to any other items used in its preparation.\n* Participation in another clinical trial in the past 30 days.\n* Pregnant or at risk of pregnancy.\n* Taking a prohibited medication. Some medications to treat UP/UPS are prohibited during participation in the study, including laxatives and anti-diarrhea medications; however, oral 5-ASA agents at doses up to 4.8 g/day and daily fiber supplements are allowed. Other medications (e.g., antibiotics, anti-seizure and anti-coagulant medicines) are also prohibited.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieved Remission","description":"Remission was a combined assessment of clinical and endoscopic variables, defined as an endoscopy score of less than or equal to (\\<=) 1, a rectal bleeding score of 0, and an improvement or no change from baseline in stool frequency subscales of the Modified Mayo Disease Activity Index (MMDAI) at the end of 6 weeks of treatment. MMDAI was used to assess the overall disease activity for each participant. MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment (PGA) and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Stool frequency MMDAI subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Endoscopy MMDAI subscore ranged from 0-3, where 0 indicated normal or inactive disease and 3 indicated severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null},{"groupId":"OG001","value":"22.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Rectal Bleeding MMDAI Subscale Score of 0 at End of Week 6","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices:stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Missing data was imputed using LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Scheduled Assessments With Rectal Bleeding Responder Classification","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Percentage of participants who were rectal bleeding responder at scheduled assessments were reported. Rectal bleeding responders were defined as those participants who achieved a rectal bleeding MMDAI subscale score of 0 during the treatment period. Missing data was imputed using LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an Endoscopy MMDAI Subscale Score of 0 or 1 at End of Week 6","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscale ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease, 2 = moderate disease and 3 = severe disease (spontaneous bleeding, ulceration). Percentage of participants with normal or mild disease have been presented in this outcome measure. Missing data was imputed using LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"36.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Score of 0 for Rectal Bleeding Subscale and a Combined Score of <=2 for Bowel Frequency (BF) and Physician's Global Assessment (PGA) in the MMDAI Subscales at End of Week 6","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal disease and 3 indicated severe disease. Missing data was imputed using LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.3","spread":null},{"groupId":"OG001","value":"23.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved an MMDAI Total Score of <= 3 With Greater Than or Equal to (>=2) Points of Improvement From Baseline at the End of Week 6","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Improvement of >=1 Point From Baseline in the MMDAI Endoscopy Subscale Score at End of Week 6","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscore ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern), 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions), and 3 = severe disease (spontaneous bleeding, ulceration). Missing data was imputed using LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.5","spread":null},{"groupId":"OG001","value":"38.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Improvement of >=1 Point From Baseline in the MMDAI Rectal Bleeding Subscale Score at End of Week 6","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, and 3 indicated blood alone passed. Missing data was imputed using LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"56.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved >=3 Point Improvement From Baseline in the MMDAI Total Score Including Improvement of >=1 Point From Baseline in the MMDAI Rectal Bleeding Subscale Score and MMDAI Endoscopy Subscale at End of Week 6","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null},{"groupId":"OG001","value":"34.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 6 in MMDAI Total Score and Subscale Scores","description":"The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.95"},{"groupId":"OG001","value":"1.8","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.99"},{"groupId":"OG001","value":"-0.5","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.39"},{"groupId":"OG001","value":"2.1","spread":"0.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"0.97"},{"groupId":"OG001","value":"-0.9","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.26"},{"groupId":"OG001","value":"2.0","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.91"},{"groupId":"OG001","value":"-0.6","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.33"},{"groupId":"OG001","value":"2.1","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.92"},{"groupId":"OG001","value":"-0.5","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"1.25"},{"groupId":"OG001","value":"8.0","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"3.20"},{"groupId":"OG001","value":"-2.5","spread":"2.72"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":134},"commonTop":["Blood cortisol decreased","Headache","Urinary tract infection","Abdominal pain","Nasopharyngitis"]}}}